ASX Release

25 November 2026

Retirement of Nick England, Pharmx Chair

Pharmx Technologies Limited (ASX: PHX) (Pharmx, the Company) announces that as discussed at today's Annual General Meeting, Nick England will be retiring from his position of Chairman of the Board.

Nick joined the Board in 2019 and was appointed as Chair in 2020. During this time Nick guided the Company through the acquisition of Pharmx, the divestment of the software business and the creation of new opportunities for the Pharmx platform. Nick will be retiring effective 31 December 2026.

Jon Newbery succeeds Nick as Chairman of the Board. Jon has been a Director of the Company since 2020. He brings a wealth of experience to the role as well as a deep understanding of the business.

Nick said:
"After seven years as director and most of that time as Chair, the time is right for me to retire. I am delighted Jon has agreed to succeed me as Chair and I believe that the Company could not be in better hands. I plan to remain a shareholder in Pharmx and follow closely from the sidelines."

Jon said:
"I am looking forward to stepping into the Chair position and continuing to build on the legacy Nick has built. The company is well placed for its next phase of growth, and I am confident in the strength of the Board, the management team and in the Company's future."

ENDS

This announcement has been authorised for release by the Board of Directors

For further information contact:

Tom Culver
Chief Executive Officer
investor.relations@pharmx.com.au

About Pharmx Technologies Limited

Pharmx is ANZ's leading pharmacy ordering platform, providing essential infrastructure for seamless ordering and inventory management. By connecting the largest network of pharmacies, suppliers, and technology vendors, Pharmx facilitates over $20 billion in transactions annually through its robust, high-availability technology platform – driving efficient operations, seamless connectivity, and valuable insights across its ordering, eInvoicing, and analytics solutions.

Operating in a dynamic and evolving market, Pharmx is positioned for sustained growth, driven by population growth, demographic shifts, and regulatory changes. With a strategic focus on expanding its addressable market, Pharmx leverages its extensive network, proprietary pharma-tech, and advanced data capabilities to unlock new revenue opportunities and enhance healthcare outcomes across Australia and New Zealand.

PO BOX Q281
Queen Victoria Building
Sydney, NSW 1230
1300 724 579

info@Pharmx.com.au
www.Pharmx.com.au
ABN: 25 000 091 305
ACN: 000 091 305